These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 34011628)

  • 21. Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression.
    Donovan DM; Miner LL; Perry MP; Revay RS; Sharpe LG; Przedborski S; Kostic V; Philpot RM; Kirstein CL; Rothman RB; Schindler CW; Uhl GR
    Brain Res Mol Brain Res; 1999 Nov; 73(1-2):37-49. PubMed ID: 10581396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
    Sconce MD; Churchill MJ; Greene RE; Meshul CK
    Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats.
    Lin CH; Huang JY; Ching CH; Chuang JI
    J Pineal Res; 2008 Mar; 44(2):205-13. PubMed ID: 18289173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys.
    Johnston LC; Eberling J; Pivirotto P; Hadaczek P; Federoff HJ; Forsayeth J; Bankiewicz KS
    Hum Gene Ther; 2009 May; 20(5):497-510. PubMed ID: 19203243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the weaver mutation on the expression of dopamine membrane transporter, tyrosine hydroxylase and vesicular monoamine transporter in dopaminergic neurons of the substantia nigra and the ventral tegmental area.
    Adelbrecht C; Agid Y; Raisman-Vozari R
    Brain Res Mol Brain Res; 1996 Dec; 43(1-2):291-300. PubMed ID: 9037545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function.
    Oaks AW; Frankfurt M; Finkelstein DI; Sidhu A
    PLoS One; 2013; 8(4):e60378. PubMed ID: 23560093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.
    Khodr CE; Becerra A; Han Y; Bohn MC
    Brain Res; 2014 Mar; 1550():47-60. PubMed ID: 24463035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
    Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
    Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individual parkinsonian motor signs and striatal dopamine transporter deficiency: a study with [I-123]FP-CIT SPECT.
    Mäkinen E; Joutsa J; Jaakkola E; Noponen T; Johansson J; Pitkonen M; Levo R; Mertsalmi T; Scheperjans F; Kaasinen V
    J Neurol; 2019 Apr; 266(4):826-834. PubMed ID: 30687897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal parkinsonism in the elderly is associated with striatal dopamine loss and pontine structural damage.
    Chung SJ; Yoo HS; Lee YH; Sohn YH; Ye BS; Cha J; Lee PH
    Parkinsonism Relat Disord; 2020 Dec; 81():140-143. PubMed ID: 33130476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine transporter and vesicular monoamine transporter knockout mice : implications for Parkinson's disease.
    Miller GW; Wang YM; Gainetdinov RR; Caron MG
    Methods Mol Med; 2001; 62():179-90. PubMed ID: 21318776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson's disease model.
    Qi X; Davis B; Chiang YH; Filichia E; Barnett A; Greig NH; Hoffer B; Luo Y
    J Neurochem; 2016 Sep; 138(5):746-57. PubMed ID: 27317935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-specific overexpression of COMT in dopaminergic neurons of Parkinson's disease.
    Kuzumaki N; Suda Y; Iwasawa C; Narita M; Sone T; Watanabe M; Maekawa A; Matsumoto T; Akamatsu W; Igarashi K; Tamura H; Takeshima H; Tawfik VL; Ushijima T; Hattori N; Okano H; Narita M
    Brain; 2019 Jun; 142(6):1675-1689. PubMed ID: 31135049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
    Watanabe Y; Himeda T; Araki T
    Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions.
    Perona MT; Waters S; Hall FS; Sora I; Lesch KP; Murphy DL; Caron M; Uhl GR
    Behav Pharmacol; 2008 Sep; 19(5-6):566-74. PubMed ID: 18690111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.
    Masoud ST; Vecchio LM; Bergeron Y; Hossain MM; Nguyen LT; Bermejo MK; Kile B; Sotnikova TD; Siesser WB; Gainetdinov RR; Wightman RM; Caron MG; Richardson JR; Miller GW; Ramsey AJ; Cyr M; Salahpour A
    Neurobiol Dis; 2015 Feb; 74():66-75. PubMed ID: 25447236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cis-acting elements responsible for dopaminergic neuron-specific expression of zebrafish slc6a3 (dopamine transporter) in vivo are located remote from the transcriptional start site.
    Bai Q; Burton EA
    Neuroscience; 2009 Dec; 164(3):1138-51. PubMed ID: 19755139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia.
    Ittner LM; Fath T; Ke YD; Bi M; van Eersel J; Li KM; Gunning P; Götz J
    Proc Natl Acad Sci U S A; 2008 Oct; 105(41):15997-6002. PubMed ID: 18832465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of the sonic hedgehog receptor smoothened on the survival and function of dopaminergic neurons.
    Zhou X; Pace J; Filichia E; Lv T; Davis B; Hoffer B; Selman W; Luo Y
    Exp Neurol; 2016 Sep; 283(Pt A):235-45. PubMed ID: 27317298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.